KIF20A and neoplasm: As recently reviewed by Moon, multiple MKLP2 vaccines have been evaluated in phase I clinical trials, including in advanced NSCLC and SCLC patients, and have demonstrated tolerability and encouraging abilities to antagonize several tumour types [92].